NMDA receptor (glycine site) + dopamine/5-HT receptor

Class

NMDA modulator + atypical antipsychotic combination

This mechanism combines two distinct neurotransmitter systems to address complex mood disorders. The first component acts at the glycine-binding site of the NMDA receptor, a subtype of glutamate receptor that requires simultaneous binding of glutamate and glycine (or a related co-agonist) to open its ion channel. Glutamate is the principal excitatory neurotransmitter in the brain, and modulating NMDA receptor activity through this co-agonist site can influence synaptic plasticity and mood-related circuits without directly flooding the glutamate-binding site itself, which is thought to reduce excitotoxic risk. The second component engages dopamine and serotonin (5-HT) receptors, the mechanism underlying atypical antipsychotic agents, which dampen dopaminergic signaling implicated in psychosis and agitation while serotonergic activity contributes to mood regulation and can offset movement-related side effects. Pairing an NMDA glycine-site modulator with a dopamine/serotonin-modulating agent aims to address mood pathology and any accompanying psychotic or agitated features concurrently, while also using the antipsychotic component to temper stimulant or psychotomimetic effects that glutamatergic modulation can sometimes produce. This dual-pathway approach is of interest in severe depressive states, particularly those with agitation or suicidality, where affecting glutamatergic and monoaminergic systems together may offer broader symptom coverage than either mechanism alone.